In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

it does not neglect the related information within the areas outside the pleural effusion. It has been reported that the primary tumour cannot be found in approximately 10% of MPEs.24 Therefore, it is ...

A 34-year-old man was admitted to the hospital because of left ear pain with hearing loss and facial droop on the left side. Computed tomography showed a nasopharyngeal mass. A diagnosis was made.

Nat Clin Pract Neurol. 2007;3(1):24-35. In the absence of these typical radiographic features, diagnosis of early stages of PCNSL is challenging. Early PCNSLs might appear as poorly enhancing and ...

Stage 4 lymphoma is a cancer of white blood cells called lymphocytes that has spread outside the lymph nodes to other parts of the body. While this is an advanced stage, treatment options are ...

EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma. The decision follows the Committee for Medicinal Products for Human Use’s ... on the Phase III HD21 trial outcomes, which showed ...

T-cell lymphoma starts in lymph tissue which is found throughout the body, such as in the spleen, tonsils, bone marrow, intestines, and skin. Most skin (cutaneous) lymphomas are T-cell lymphomas.

There are 2 main types of lymphoma: Hodgkin lymphoma (HL) Non-Hodgkin lymphoma (NHL) HL and NHL come from different types of cells. They behave, spread, and respond to treatment differently, so it's ...